INVESTIGATOR PERSPECTIVES Application of a Tissue-Free Epigenomic Assay to Improve MRD Detection in Previously Treated CRC
home / investigator-perspectives / investigator-perspectives-application-of-a-tissue-free-epigenomic-assay-to-improve-mrd-detection
Yoshiaki Nakamura, MD, PhD, discusses how a methylation-based circulating tumor DNA assay can enhance minimal residual disease detection and improve prognosis in patients with previously treated stage II-III colorectal cancer.
EP. 1: Risk of Recurrent Colorectal Cancer Following Definitive Therapy
September 30th 2024Yoshiaki Nakamura, MD, PhD, discusses how the use of tissue-free circulating tumor DNA (ctDNA) analysis for detecting minimal residual disease (MRD) can enhance the prediction of recurrence in stage II to III colorectal cancer (CRC), particularly when tumor specimens are limited.
Watch
